Treats metastatic carcinoid tumors. ANDA 76313, held by West-Ward Pharms Int. Octreotide Acetate.
As of Nov 16, 2026, ANDA 76313 (Octreotide Acetate (Preservative Free)), held by West-Ward Pharms Int, was first approved by FDA on Mar 28, 2005, with 7 approved supplements and 0 published complete response letters.
Octreotide acetate injection is a somatostatin analogue indicated: Acromegaly: To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Carcinoid Tumors: For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Vasoactive Intestinal Peptide Tumors (VIPomas): For the treatment of profuse watery diarrhea associated with VIP-secreting tumors.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 2005 | Original application | Approved |
| Octreotide Acetate (Preservative Free)EQ 0.05MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide Acetate (Preservative Free)EQ 0.5MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide Acetate (Preservative Free)EQ 0.1MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Sep 16, 2022 | Supplement 21Labeling · Standard review | Approved | None posted |
| Sep 16, 2022 | Supplement 19Labeling · Standard review | Approved | None posted |
| Sep 16, 2022 | Supplement 16Labeling · Standard review | Approved | None posted |
| Aug 27, 2018 | Supplement 13Manufacturing | Approved | None posted |
| Aug 27, 2018 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 2, 2013 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 3, 2009 | Supplement 3Labeling | Approved | None posted |
| Mar 28, 2005 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters